You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

46 Results
Guidelines and Advice
Status: Current
ID: GL 4-1
Version: 2
Jan 2021
Guidelines and Advice
Status: In-Review
ID: GL 2-24
May 2019
Guidelines and Advice
Status: Archived
ID: 2-14
Version: 3
Apr 2011
Symptom Management
Symptom Management
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and No Prior mTOR Inhibitor
New Drug Funding Program
    Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and Prior mTOR Inhibitor
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2024
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
New Drug Funding Program
    Nivolumab - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma
New Drug Funding Program
    Nivolumab - Adjuvant Treatment for Completely Resected Stage III or IV Melanoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
nivolumab (Unfunded),
ipilimumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet ((multiple cancer types))
Mar 2025
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma
New Drug Funding Program
    Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab,
ipilimumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet ((multiple cancer types))
Mar 2025
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Drugs Used:
nivolumab (Unfunded),
ipilimumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet ((multiple cancer types))
Mar 2025
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab,
ipilimumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet ((multiple cancer types))
Mar 2025
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Malignant Pleural Mesothelioma
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Malignant Pleural Mesothelioma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab,
ipilimumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet ((Lung))
Mar 2025

Pages